The correlation between HbA1c and fasting plasma glucose (FPG) is central to diagnosing and monitoring diabetes in NHS clinical practice. Both tests measure glycaemic control but capture different physiological processes — HbA1c reflects average blood glucose over two to three months, whilst FPG provides a snapshot of baseline glucose regulation. Understanding how these markers relate, where they align, and why they sometimes diverge is essential for clinicians and patients alike. This article explains the clinical relationship between HbA1c and FPG, how each is measured, and how UK guidance from NICE, WHO, and Diabetes UK informs their interpretation.

Understanding HbA1c and Fasting Plasma Glucose in Diabetes Diagnosis

HbA1c reflects average blood glucose over 2–3 months, whilst FPG is a snapshot of baseline glucose regulation; both are recognised by NICE and WHO as valid diagnostic tools for type 2 diabetes, though each has specific clinical limitations.

Diabetes mellitus is diagnosed using biochemical markers that reflect different aspects of glycaemic control. Two of the most widely used tests are haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG). Understanding what each test measures — and how they relate to one another — is essential for both clinicians and patients navigating a diabetes diagnosis or monitoring long-term glucose management.

HbA1c reflects the proportion of haemoglobin molecules that have been glycated (bound to glucose) over the preceding two to three months. Because red blood cells have a lifespan of approximately 120 days, HbA1c provides a reliable retrospective picture of average blood glucose levels. It is expressed in millimoles per mole (mmol/mol) in the UK, following the IFCC standardisation adopted by the NHS.

Fasting plasma glucose (FPG), by contrast, is a snapshot measurement taken after a minimum of eight hours without caloric intake. It reflects the body's baseline glucose regulation — primarily governed by hepatic glucose output and fasting insulin sensitivity. A raised FPG indicates impaired fasting glucose or frank diabetes, depending on the threshold reached.

Both markers are recognised by NICE, the World Health Organization (WHO), and Diabetes UK as valid diagnostic tools for type 2 diabetes in appropriate clinical circumstances. However, they capture different physiological processes, which is why their values do not always align perfectly.

Important limitations on the use of HbA1c for diagnosis

HbA1c should not be used as the primary diagnostic test in the following situations, where plasma glucose testing (FPG or oral glucose tolerance test) is preferred instead:

• Children and young people — HbA1c is not recommended for diagnosing diabetes in those under 18 years.

• Suspected type 1 diabetes — diagnosis should be based on symptoms and plasma glucose; HbA1c may be misleading in acute or rapid-onset presentations.

• Pregnancy — gestational diabetes is diagnosed using an oral glucose tolerance test (OGTT).

• Acute hyperglycaemic illness or recent onset of symptoms — HbA1c may not yet reflect the degree of hyperglycaemia.

• Conditions affecting red cell turnover or haemoglobin structure (see below).

Understanding these distinctions is the foundation for interpreting the correlation between HbA1c and FPG in clinical practice.

How HbA1c and Fasting Plasma Glucose Are Measured in the NHS

HbA1c requires no fasting and is reported in mmol/mol (diagnostic threshold ≥48 mmol/mol), whilst FPG requires ≥8 hours of fasting and is diagnostic at ≥7.0 mmol/L; conditions such as iron deficiency anaemia and haemoglobinopathies can affect HbA1c reliability.

In the NHS, both HbA1c and fasting plasma glucose are routinely measured through blood tests, though the preparation and methodology differ between them. Knowing how each test is conducted helps patients understand why results may sometimes appear inconsistent with one another.

HbA1c testing requires a venous blood sample, which is typically sent to an accredited laboratory for analysis. No fasting is required before an HbA1c test, making it more convenient for many patients. The sample is analysed using high-performance liquid chromatography (HPLC) or immunoassay methods, standardised to the IFCC reference system. In the UK, results are reported in mmol/mol, with a diagnostic threshold for diabetes set at 48 mmol/mol or above.

Fasting plasma glucose requires the patient to fast for at least eight hours prior to the blood draw, usually taken first thing in the morning. The sample is processed to measure the concentration of glucose in the plasma, reported in millimoles per litre (mmol/L). A fasting glucose of 7.0 mmol/L or above, confirmed on a second occasion in asymptomatic individuals, is diagnostic of diabetes according to NHS and WHO criteria.

Certain conditions can affect the reliability of each test:

• HbA1c may be falsely low in haemolytic anaemia, haemoglobinopathies (e.g., sickle cell disease or trait), or during pregnancy.

• HbA1c may be falsely elevated in iron deficiency anaemia, which is a common and clinically important cause of spuriously raised results.

• Haemoglobin variants can either raise or lower HbA1c depending on the assay method used; clinicians should check their local laboratory's assay-specific interference statement when a haemoglobinopathy is known or suspected.

• Renal impairment can alter red cell turnover and affect HbA1c reliability.

• FPG can be transiently elevated due to acute illness, physiological stress, or certain medications such as corticosteroids.

NHS laboratories providing HbA1c and plasma glucose testing operate under UKAS accreditation (ISO 15189) and participate in UK NEQAS (National External Quality Assessment Service) external quality assurance schemes. These frameworks ensure analytical accuracy and comparability of results across NHS sites. Clinicians must always interpret results in the context of the individual patient's clinical picture.

The Clinical Relationship Between HbA1c and FPG Levels

HbA1c and FPG show a positive correlation, but post-prandial glucose excursions, anaemia, haemoglobinopathies, renal impairment, and ethnicity can all cause the two markers to diverge.

The correlation between HbA1c and FPG is well established in the medical literature, though it is not a perfect linear relationship. Both markers rise as glycaemic control deteriorates, but they do so at different rates and in response to different physiological mechanisms — which explains why discordance between the two is not uncommon in clinical practice.

Research consistently demonstrates a positive correlation between HbA1c and FPG: as fasting glucose rises, HbA1c tends to rise in parallel. This is because chronically elevated fasting glucose contributes significantly to overall glycaemic exposure, which in turn drives glycation of haemoglobin. Various regression equations have been proposed to estimate one value from the other, though these are used for research purposes rather than clinical diagnosis.

Several factors can cause the two markers to diverge:

• Post-prandial glucose excursions contribute substantially to HbA1c but are not captured by FPG alone. A patient with normal fasting glucose but significant post-meal spikes may have a disproportionately elevated HbA1c.

• Iron deficiency anaemia can falsely elevate HbA1c, leading to apparent discordance with plasma glucose results.

• Haemological conditions — including haemolytic anaemia and haemoglobin variants — can suppress or elevate HbA1c independently of true glucose levels, depending on the assay method.

• Renal impairment can alter red cell turnover, affecting HbA1c reliability.

• Ethnicity — some studies have observed that individuals of South Asian or African-Caribbean descent may have higher HbA1c values at equivalent plasma glucose concentrations. However, no UK body currently recommends ethnicity-specific diagnostic thresholds; clinicians should be aware of this observed variation and interpret results in the full clinical context, but should apply standard UK diagnostic cut-offs.

Understanding these nuances is critical when interpreting apparently conflicting results between the two tests.

Using Both Markers Together for Accurate Diabetes Assessment

HbA1c is preferred for monitoring chronic hyperglycaemia, whilst FPG is more sensitive to acute changes; when results are discordant, NICE advises repeating the discordant test rather than automatically diagnosing or excluding diabetes.

HbA1c and FPG each have distinct strengths and limitations. UK guidance — from NICE, the WHO, and Diabetes UK — does not recommend routine dual testing for diagnosis. The standard approach is to select the most appropriate test for the individual patient, and to confirm an abnormal result with a repeat of the same test in asymptomatic individuals, or with a second test if the first is borderline or discordant.

In clinical practice, the two tests complement each other in the following ways:

• HbA1c is better suited to identifying chronic, sustained hyperglycaemia and is less susceptible to day-to-day variability. It is the preferred monitoring tool for patients already diagnosed with diabetes.

• FPG is more sensitive to acute changes in glucose regulation and can detect impaired fasting glucose — a high-risk state — even when HbA1c remains within the normal range.

• When one test is borderline and the other is clearly abnormal, the abnormal result should prompt further clinical evaluation rather than dismissal.

• When results are discordant (one above and one below the diagnostic threshold), NICE advises repeating the discordant test rather than automatically diagnosing or excluding diabetes.

High-risk (non-diabetic hyperglycaemia)

The NHS Diabetes Prevention Programme (NHS DPP), commissioned by NHS England and OHID, uses the following eligibility thresholds for identifying people at high risk:

• HbA1c 42–47 mmol/mol, and/or

• FPG 5.5–6.9 mmol/L

Note that the WHO defines impaired fasting glucose (IFG) as FPG 6.1–6.9 mmol/L; the NHS DPP uses a lower FPG entry threshold of 5.5 mmol/L to capture a broader high-risk population. Clinicians should use the appropriate threshold depending on the clinical context (diagnostic versus prevention programme referral).

Lifestyle interventions, including dietary modification and increased physical activity, have been shown to improve both HbA1c and FPG simultaneously, reinforcing their shared physiological basis.

When to seek urgent assessment

Patients should seek same-day urgent medical assessment if they experience any of the following, regardless of previous test results:

• Rapid or unexplained weight loss

• Severe thirst, frequent urination, and fatigue developing over days to weeks (possible type 1 diabetes or hyperglycaemic emergency)

• Vomiting, abdominal pain, or drowsiness alongside high blood glucose (possible diabetic ketoacidosis — DKA)

• Confusion, extreme dehydration, or reduced consciousness (possible hyperosmolar hyperglycaemic state — HHS)

These presentations require emergency assessment and should not await routine blood test results.

NICE Guidance on Interpreting HbA1c and Fasting Glucose in Practice

NICE requires two separate abnormal results to diagnose diabetes in asymptomatic individuals, and recommends FPG or OGTT when HbA1c is unreliable; no UK body currently recommends ethnicity-adjusted diagnostic thresholds.

NICE guidance, WHO diagnostic criteria, and the Diabetes UK/UK consensus position on HbA1c for diagnosis together provide the framework for interpreting HbA1c and fasting plasma glucose in NHS clinical practice. NICE guideline NG28 (Type 2 diabetes in adults: management) addresses ongoing management; diagnostic recommendations are set out in the NICE Pathway for Type 2 diabetes: diagnosis and management and are aligned with WHO criteria.

Diagnostic thresholds (WHO/NICE/NHS)

| Category | HbA1c | FPG | |---|---|---| | Diabetes | ≥ 48 mmol/mol | ≥ 7.0 mmol/L | | Non-diabetic hyperglycaemia (high risk) | 42–47 mmol/mol | 5.5–6.9 mmol/L (NHS DPP) / 6.1–6.9 mmol/L (WHO IFG) | | Normal | < 42 mmol/mol | < 6.1 mmol/L |

NICE recommends that a single abnormal result is sufficient for diagnosis in symptomatic individuals, but that two separate abnormal results are required in asymptomatic patients. If HbA1c and FPG give discordant results (one above and one below the diagnostic threshold), NICE advises repeating the discordant test rather than automatically diagnosing or excluding diabetes.

When HbA1c should not be used for diagnosis

For patients in whom HbA1c is unreliable or not appropriate — including those with haemoglobinopathies, haemolytic anaemia, iron deficiency anaemia, renal impairment, children and young people, suspected type 1 diabetes, or during pregnancy — NICE and Diabetes UK recommend using FPG or an oral glucose tolerance test (OGTT) as the primary diagnostic tool.

Ethnicity and diagnostic thresholds

Whilst observed differences in the HbA1c–FPG relationship across ethnic groups are acknowledged in the literature, no UK body currently recommends adjusted diagnostic cut-offs based on ethnicity. Standard thresholds should be applied, with clinical judgement used to contextualise borderline results.

Prevention programme referral

Patients with non-diabetic hyperglycaemia (HbA1c 42–47 mmol/mol and/or FPG 5.5–6.9 mmol/L) should be offered referral to the NHS Diabetes Prevention Programme where eligible, alongside structured education, lifestyle support, and regular follow-up. This programme has been shown to reduce progression to type 2 diabetes in high-risk individuals.

Healthcare professionals should always interpret biochemical results alongside the full clinical picture, and should not delay urgent assessment where symptoms suggest a hyperglycaemic emergency or type 1 diabetes.

Frequently Asked Questions